However, a significantly lower risk of ovarian hyperstimulation syndrome (OHSS) (22 trials, 5598 women) was found with the use of GnRH antagonists compared to the long GnRH agonist protocol (44). This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.